Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Hyung-Heon Kim | CEO, President & Director | 625.16k | -- | 1975 |
| Mr. Marshall H. Woodworth | Chief Financial Officer | 154.5k | -- | 1958 |
| Dr. Mi-Kyung Kim | Chief Scientific Officer | -- | -- | -- |
| Mr. Robert Homolka | Senior Vice President of Clinical Operations | -- | -- | -- |
MetaVia Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8
Description
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
November 7, 2024 at 1:01 PM UTC
MetaVia Inc. Earnings Date
Recent Events
December 31, 2019 at 12:00 AM UTC
Dividend Date